Literature DB >> 10674679

No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine.

M van Vugt1, F Ezzet, F Nosten, I Gathmann, P Wilairatana, S Looareesuwan, N J White.   

Abstract

Artemether-lumefantrine is a new fixed antimalarial combination effective against multidrug-resistant falciparum malaria. A prospective electrocardiographic study was conducted in 150 patients receiving artemetherlumefantrine and 50 treated with artesunate-mefloquine. There was no evidence for clinically significant changes in the electrocardiographic intervals and in particular no relationship between plasma concentrations of lumefantrine and QTc prolongation. Artemether-lumefantrine does not have significant cardiac effects at therapeutic doses.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10674679     DOI： 10.4269/ajtmh.1999.61.964

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  22 in total

Review 1.  Unresolved antiretroviral treatment management issues in HIV-infected children.

Authors:  Shirin Heidari; Lynne M Mofenson; Charlotte V Hobbs; Mark F Cotton; Richard Marlink; Elly Katabira
Journal:  J Acquir Immune Defic Syndr       Date:  2012-02-01       Impact factor: 3.731

Review 2.  Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria.

Authors:  A A A Omari; C Gamble; P Garner
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

3.  Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria.

Authors:  Abdoulaye A Djimdé; Mamadou Tekete; Salim Abdulla; John Lyimo; Quique Bassat; Inacio Mandomando; Gilbert Lefèvre; Steffen Borrmann
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 4.  Antimalarial drug toxicity: a review.

Authors:  W Robert J Taylor; Nicholas J White
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  Evaluation of the efficacy and safety of artemether-lumefantrine in the treatment of acute uncomplicated Plasmodium falciparum malaria in Nigerian infants and children.

Authors:  Catherine O Falade; Oluwatoyin O Ogunkunle; Hannah O Dada-Adegbola; Adegoke G Falade; Patricia Ibarra de Palacios; Philip Hunt; Mailis Virtanen; Ayoade M Oduola; Lateef A Salako
Journal:  Malar J       Date:  2008-11-27       Impact factor: 2.979

6.  Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.

Authors:  Stephan Ehrhardt; Christian G Meyer
Journal:  Ther Clin Risk Manag       Date:  2009-10-12       Impact factor: 2.423

7.  Therapeutic efficacy of Artemether/Lumefantrine (Coartem(R)) against Plasmodium falciparum in Kersa, South West Ethiopia.

Authors:  Ashenafi Assefa; Moges Kassa; Gemechu Tadese; Hussen Mohamed; Abebe Animut; Tesfayae Mengesha
Journal:  Parasit Vectors       Date:  2010-01-05       Impact factor: 3.876

Review 8.  Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base.

Authors:  Olivier Bouchaud; Patrick Imbert; Jean Etienne Touze; Alex N O Dodoo; Martin Danis; Fabrice Legros
Journal:  Malar J       Date:  2009-12-10       Impact factor: 2.979

9.  Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?

Authors:  Richard J Maude; Katherine Plewes; M Abul Faiz; Josh Hanson; Prakaykaew Charunwatthana; Sue J Lee; Joel Tärning; Emran Bin Yunus; M Gofranul Hoque; Mahatab Uddin Hasan; Amir Hossain; Niklas Lindegardh; Nicholas P J Day; Nicholas J White; Arjen M Dondorp
Journal:  Am J Trop Med Hyg       Date:  2009-01       Impact factor: 2.345

10.  The effect of varying analytical methods on estimates of anti-malarial clinical efficacy.

Authors:  Wendy J Verret; Grant Dorsey; Francois Nosten; Ric N Price
Journal:  Malar J       Date:  2009-04-22       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.